[HTML][HTML] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
A Hasanova, C Asadov, N Karimova… - Pathology and …, 2023 - por-journal.com
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first-and
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia.
A Hasanova, C Asadov, N Karimova… - Pathology & …, 2024 - search.ebscohost.com
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first-and
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
[HTML][HTML] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
A Hasanova, C Asadov, N Karimova… - Pathology and …, 2023 - ncbi.nlm.nih.gov
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first-and
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
[PDF][PDF] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
A Hasanova, C Asadov, N Karimova, A Shirinova… - 2023 - researchgate.net
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first-and
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
A Hasanova, C Asadov, N Karimova… - Pathology Oncology …, 2023 - europepmc.org
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first-and
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
[PDF][PDF] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
A Hasanova, C Asadov, N Karimova, A Shirinova… - 2023 - por-journal.com
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first-and
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
[PDF][PDF] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
A Hasanova, C Asadov, N Karimova, A Shirinova… - 2023 - pdfs.semanticscholar.org
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first-and
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
A Hasanova, C Asadov, N Karimova… - Pathology …, 2023 - pubmed.ncbi.nlm.nih.gov
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first-and
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia.
A Hasanova, C Asadov, N Karimova… - Pathology Oncology …, 2023 - europepmc.org
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first-and
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …
second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) …